Nanjing Medlander Medical Technology (SH:688273)2024-01-02 08:38Group 1: Business Development Focus - The company prioritizes in-hospital markets as its core, while also exploring home-use product lines, which are currently in the cultivation stage but expected to grow significantly due to recent technological advancements [2][3] - As of mid-2023, the company's products are applied in approximately 7,400 hospitals nationwide, including over 4,100 secondary and tertiary hospitals [3] Group 2: New Product Launches - The company plans to launch three new pelvic rehabilitation products in Q1 2024, including: 1. A second-generation pelvic biological feedback device that enhances diagnostic efficiency and precision [4] 2. A new pelvic ultrasound imaging system for comprehensive clinical data acquisition [4] 3. A segmented pelvic magnet product to expand the product line and meet diverse clinical needs [4] Group 3: Financial Performance - The company's contract liabilities decreased by approximately 22 million in Q3 2023, primarily due to the delivery of last year's mold orders [4] - There are currently no adjustments planned for the 2024 performance targets, as market activities have gradually returned to normal [4] Group 4: Strategic Direction - The company aims to become a world-class medical device company focused on women's health and beauty, expanding into international markets while maintaining a dual approach of independent R&D and seeking strategic project opportunities [5] - The company emphasizes continuous innovation and product iteration based on clinical needs, particularly in the field of women's health [5]